{"id":"https://openalex.org/W2954101752","doi":"https://doi.org/10.1158/1538-7445.am2019-4108","title":"Abstract 4108: Preclinical evaluation of half-life extended Affimer\u00ae biotherapeutics targeting the PD-L1 pathway","display_name":"Abstract 4108: Preclinical evaluation of half-life extended Affimer\u00ae biotherapeutics targeting the PD-L1 pathway","publication_year":2019,"publication_date":"2019-07-01","ids":{"openalex":"https://openalex.org/W2954101752","doi":"https://doi.org/10.1158/1538-7445.am2019-4108","mag":"2954101752"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2019-4108","doi":"https://doi.org/10.1158/1538-7445.am2019-4108","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2019-4108","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5014399607","display_name":"Amrik Basran","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amrik Basran","raw_affiliation_strings":["Avacta Life Sciences, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Avacta Life Sciences, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014643231","display_name":"Emma L. Jenkins","orcid":"https://orcid.org/0000-0001-5860-8762","observed_orcids":["https://orcid.org/0000-0001-5860-8762"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Emma Jenkins","raw_affiliation_strings":["Avacta Life Sciences, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Avacta Life Sciences, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011702131","display_name":"Estelle Adam","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Estelle Adam","raw_affiliation_strings":["Avacta Life Sciences, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Avacta Life Sciences, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025097374","display_name":"Floriane Laurent","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Floriane Laurent","raw_affiliation_strings":["Avacta Life Sciences, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Avacta Life Sciences, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081478322","display_name":"Michele J. Writer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michele Writer","raw_affiliation_strings":["Avacta Life Sciences, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Avacta Life Sciences, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005723378","display_name":"Assa Oumie","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Assa Oumie","raw_affiliation_strings":["Avacta Life Sciences, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Avacta Life Sciences, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055653817","display_name":"Jyrki Sivula","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jyrki Sivula","raw_affiliation_strings":["Avacta Life Sciences, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Avacta Life Sciences, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066546006","display_name":"Maureen West","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maureen West","raw_affiliation_strings":["Avacta Life Sciences, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Avacta Life Sciences, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Emma Stanley","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Emma Stanley","raw_affiliation_strings":["Avacta Life Sciences, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Avacta Life Sciences, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085222773","display_name":"Jennifer Hillman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer Hillman","raw_affiliation_strings":["Avacta Life Sciences, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Avacta Life Sciences, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5033171081","display_name":"Viviana Robles-munoz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Viviana Robles-munoz","raw_affiliation_strings":["Avacta Life Sciences, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Avacta Life Sciences, Cambridge, United Kingdom","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"79","issue":"13_Supplement","first_page":"4108","last_page":"4108"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.6967999935150146,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.6967999935150146,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.2919999957084656,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/affimers","display_name":"Affimers","score":0.7789999842643738},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.843999981880188},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.7639999985694885},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.6349999904632568},{"id":"https://openalex.org/keywords/half-life-extension","display_name":"half-life extension","score":0.8029999732971191},{"id":"https://openalex.org/keywords/fc-fusion","display_name":"Fc fusion","score":0.7229999899864197},{"id":"https://openalex.org/keywords/serum-albumin-binding","display_name":"serum albumin binding","score":0.8500000238418579},{"id":"https://openalex.org/keywords/phage-display","display_name":"phage display","score":0.7739999890327454},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7269999980926514},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.5720000267028809},{"id":"https://openalex.org/keywords/bispecific-antibodies","display_name":"bispecific antibodies","score":0.7279999852180481},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.9359999895095825}],"concepts":[{"id":"https://openalex.org/C186268636","wikidata":"https://www.wikidata.org/wiki/Q896217","display_name":"Phage display","level":3,"score":0.5591092705726624},{"id":"https://openalex.org/C175656101","wikidata":"https://www.wikidata.org/wiki/Q56646","display_name":"Chinese hamster ovary cell","level":3,"score":0.5535663366317749},{"id":"https://openalex.org/C179223381","wikidata":"https://www.wikidata.org/wiki/Q419425","display_name":"Avidity","level":3,"score":0.5429536700248718},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.49904417991638184},{"id":"https://openalex.org/C31573885","wikidata":"https://www.wikidata.org/wiki/Q304484","display_name":"Programmed cell death","level":3,"score":0.48601990938186646},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.4720630943775177},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.45771804451942444},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.44582709670066833},{"id":"https://openalex.org/C123894998","wikidata":"https://www.wikidata.org/wiki/Q425158","display_name":"Fusion protein","level":4,"score":0.4258705675601959},{"id":"https://openalex.org/C2776471321","wikidata":"https://www.wikidata.org/wiki/Q7166526","display_name":"Peptide library","level":4,"score":0.415167897939682},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.41035863757133484},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.3885185718536377},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.37066733837127686},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3626660704612732},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.3154500722885132},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.30156630277633667},{"id":"https://openalex.org/C2779281246","wikidata":"https://www.wikidata.org/wiki/Q172847","display_name":"Peptide","level":2,"score":0.2960507273674011},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.19044527411460876},{"id":"https://openalex.org/C167625842","wikidata":"https://www.wikidata.org/wiki/Q899763","display_name":"Peptide sequence","level":3,"score":0.1823052167892456},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.16401344537734985},{"id":"https://openalex.org/C40767141","wikidata":"https://www.wikidata.org/wiki/Q285697","display_name":"Recombinant DNA","level":3,"score":0.15275421738624573},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2019-4108","doi":"https://doi.org/10.1158/1538-7445.am2019-4108","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2019-4108","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2885045294","https://openalex.org/W3179431550","https://openalex.org/W4389227772","https://openalex.org/W2955499802","https://openalex.org/W4235776243","https://openalex.org/W3196632722","https://openalex.org/W2165838507","https://openalex.org/W6958534742","https://openalex.org/W3011651125","https://openalex.org/W2565822857"],"abstract_inverted_index":{"Abstract":[0],"Programmed":[1,10],"Cell":[2,11],"Death-Ligand":[3],"1":[4,80],"(PD-L1)":[5],"binds":[6],"to":[7,73,171,197,207,217,221,271,308],"its":[8],"receptor,":[9],"Death":[12],"protein":[13,123],"(PD-1)":[14],"and":[15,25,31,49,76,107,139,181,225,255,287,305],"is":[16,26],"expressed":[17],"on":[18,125,252],"a":[19,57,66,99,119,165],"range":[20,67,166],"of":[21,59,68,167,189,227,239,347,359],"activated":[22],"immune":[23,33],"cells":[24,30,34,222],"upregulated":[27],"by":[28,32,149,177,195],"tumor":[29,37],"in":[35,50,56,98,105,108,110,151,223,243,293,318],"the":[36,126,159,228,240,253,264,268,319,353,360],"microenvironment.":[38],"PD-L1":[39,175,354],"immunotherapies":[40],"have":[41,64,83,91,146,163,261],"emerged":[42],"as":[43,47,87,136,201,274,284],"effective":[44],"treatments":[45],"both":[46,74,303],"monotherapies":[48],"combinations,":[51],"providing":[52],"long":[53],"term":[54],"responses":[55],"subset":[58],"patients.":[60],"Phage":[61],"display":[62,144],"selections":[63],"identified":[65,164],"potent":[69],"Affimer":[70,116,191,265,279],"biotherapeutic":[71],"antagonists":[72],"human":[75,127,174,198],"mouse":[77,100,114,172,244],"programmed":[78],"death-ligand":[79],"(PD-L1).":[81],"We":[82,162,212,260],"demonstrated":[84,213,262],"when":[85],"formatted":[86,185,241,283],"bivalent":[88],"molecules":[89,297],"they":[90],"improved":[92],"sub":[93],"nM":[94],"affinity,":[95],"half-life":[96,246,256,348],"extension":[97,188,247,257],"PK":[101,237],"study,":[102],"blocking":[103],"activity":[104],"vitro":[106,224],"vivoefficacy":[109],"syngeneic":[111],"or":[112,173,200],"xenograph":[113],"models.":[115],"biotherapeutics":[117,351],"are":[118],"14kDa":[120],"monomeric":[121],"scaffold":[122,160,266,280],"based":[124,234],"protease":[128],"inhibitor":[129],"Stefin":[130],"A,":[131],"lacking":[132],"post-translational":[133],"modifications":[134],"such":[135],"disulfide":[137],"bonds":[138],"glycosylation.":[140],"Large":[141],"diverse":[142],"phage":[143],"libraries":[145],"been":[147],"created":[148],"engineering":[150],"two":[152],"nine":[153],"amino":[154],"acid":[155],"peptide":[156],"loops":[157],"into":[158],"backbone.":[161],"affinity":[168],"competitive":[169],"binders":[170],"confirmed":[176],"performing":[178],"competition":[179],"ELISA":[180],"SPR":[182],"using":[183,231],"Fc":[184,285],"antigen.":[186],"Half-life":[187],"lead":[190],"proteins":[192,281],"was":[193],"achieved":[194],"fusing":[196],"IgG1Fc":[199],"an":[202,275],"in-line":[203,288],"fusion":[204,286,289],"(ILF)":[205],"fused":[206],"serum":[208],"albumin":[209],"binding":[210,216,220],"Affimers.":[211],"avidity":[214],"for":[215,302,363],"target":[218],"antigen,":[219],"blockade":[226],"PD-1L/PD-1":[229],"interaction":[230],"Promega":[232],"cell":[233],"assay.":[235],"The":[236,277],"properties":[238,270],"Affimers":[242],"showed":[245,292],"from":[248],"40-120":[249],"hours":[250],"depending":[251],"clone":[254],"technology":[258],"used.":[259],"that":[263,313],"has":[267],"necessary":[269],"be":[272,299],"developed":[273,300],"immunotherapy.":[276],"anti-PD-L1":[278],"were":[282],"formats":[290],"which":[291],"vivo":[294],"efficacy.":[295],"These":[296],"will":[298,314],"further":[301],"bispecific":[304],"drug":[306],"conjugates":[307],"generate":[309],"new":[310],"novel":[311],"biotheraputics":[312],"give":[315],"greater":[316],"efficacy":[317],"clinic.":[320],"Citation":[321],"Format:":[322],"Amrik":[323],"Basran,":[324],"Emma":[325,339],"Jenkins,":[326],"Estelle":[327],"Adam,":[328],"Floriane":[329],"Laurent,":[330],"Michele":[331],"Writer,":[332],"Assa":[333],"Oumie,":[334],"Jyrki":[335],"Sivula,":[336],"Maureen":[337],"West,":[338],"Stanley,":[340],"Jennifer":[341],"Hillman,":[342],"Viviana":[343],"Robles-munoz.":[344],"Preclinical":[345],"evaluation":[346],"extended":[349],"Affimer\u00ae":[350],"targeting":[352],"pathway":[355],"[abstract].":[356],"In:":[357],"Proceedings":[358],"American":[361],"Association":[362],"Cancer":[364,378],"Research":[365],"Annual":[366],"Meeting":[367],"2019;":[368],"2019":[369],"Mar":[370],"29-Apr":[371],"3;":[372],"Atlanta,":[373],"GA.":[374],"Philadelphia":[375],"(PA):":[376],"AACR;":[377],"Res":[379],"2019;79(13":[380],"Suppl):Abstract":[381],"nr":[382],"4108.":[383]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2020,"cited_by_count":1}],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2019-07-12T00:00:00"}